Maruho launches Mitchga, a novel antibody drug originated by Chugai
Japanese drugmaker Maruho has launched the anti-interleukin (IL)-31 receptor A humanized monoclonal antibody Mitchga (nemolizumab [genetical recombination]) subcutaneous Injection 60mg syringes for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective).
Nemolizumab was licensed to Maruho for the Japanese market in 2016 by Chugai Pharmaceutical (TYO: 4519), which is majority owned by Swiss pharma giant Roche (ROG: SIX).
Mitchga was approved by the Ministry of Health, Labor and Welfare (MHLW) on March 28, 2022 and listed on the national health insurance (NHI) reimbursement price list on May 25, 2022.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze